The start of the COVID-19 pandemic led to unprecedented exposure to stressors driven by fears of a novel and deadly disease, intense uncertainty, and resulting isolation measures, which in turn resulted in increases in anxiety for many.
The VPAS fallout continues – Celltrion pulls high-profile biosimilar from UK market – Pharmaceutical Technology
Celltrion had voiced initial worries about the likely unsustainability of the 2023 VPAS rate long before it was set last December. Credit: Pavel Kapysh /
July 3, 2023